Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PRADAXA | Boehringer Ingelheim | N-022512 RX | 2010-10-19 | 3 products, RLD, RS |
PRADAXA | Boehringer Ingelheim | N-214358 RX | 2021-06-21 | 6 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
dabigatran | ANDA | 2024-11-27 |
dabigatran etexilate | ANDA | 2025-02-11 |
pradaxa | New Drug Application | 2024-04-03 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
pulmonary embolism | EFO_0003827 | D011655 | I26 |
Expiration | Code | ||
---|---|---|---|
DABIGATRAN ETEXILATE MESYLATE, PRADAXA, BOEHRINGER INGELHEIM | |||
2024-12-21 | PED | ||
2024-06-21 | I-862, NP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Overweight | D050177 | — | E66.3 | 1 | — | — | — | — | 1 |
Covid-19 | D000086382 | — | U07.1 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 8 | 8 |
Embolism | D004617 | — | — | — | — | — | — | 2 | 2 |
Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | — | — | 2 | 2 |
Thromboembolism | D013923 | — | — | — | — | — | — | 2 | 2 |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
Thrombosis | D013927 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Dabigatran etexilate |
INN | dabigatran etexilate |
Description | Dabigatran is an aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. It has a role as an anticoagulant, an EC 3.4.21.5 (thrombin) inhibitor and an EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor. It is an aromatic amide, a member of benzimidazoles, a carboxamidine, a member of pyridines and a beta-alanine derivative. |
Classification | Small molecule |
Drug class | thrombin inhibitors (argatroban type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1 |
PDB | — |
CAS-ID | 211914-51-1 |
RxCUI | 1546356 |
ChEMBL ID | CHEMBL539697 |
ChEBI ID | 70746 |
PubChem CID | 216210 |
DrugBank | DB14726 |
UNII ID | I0VM4M70GC (ChemIDplus, GSRS) |